Figure 5.

AptBCis1 suppressed tumor growth at lower platinum concentrations. (a) The plasma and the CSF platinum concentrations were measured by ICP-MS. (b) The scheme illustrated the timeline of subcutaneous tumor cell inoculation and drug treatment in the lung cancer subcutaneous xenograft mouse model. The SELEX buffer, AptB1, AptBCis1, oligo-cisplatin or cisplatin was given via tail vein at Day 6, 7, 9, 11, 13, and 15 post tumor inoculation (n = 4 for each group). (c) Tumor size was measured daily, and the mice were sacrificed on Day 23. (d) Tumor gross pictures. (e) Body weight reduction was more obvious in the cisplatin 2 mg/kg group. Asterisks denote statistically significant differences. *P < 0.05, **P < 0.01 (unpaired t test).